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MVentilator-associated pneumonia (VAP) is the most com-
mon nosocomial infection that occurs after heart surgery
and is associated with significant morbidity and mortality.
He and colleagues1 performed a contemporary meta-
analysis summarizing the prevalence, cause, risk factors,and outcome of VAP after cardiac surgery. Results showed
that the prevalence of VAP after cardiac surgery was 6.37%,
and that the risk of mortality increased 15-fold in patients
with VAP. Several important risk factors associated with
VAP were further identified. This study highlights the scope
and significance of VAP after cardiac surgery and should
redirect attention to basic strategies for VAP prevention.
CLINICAL SUMMARY
VAP is the most common nosocomial infection that oc-
curs after heart surgery and is associated with significant
morbidity and mortality.2 He and colleagues1 performed a
contemporary meta-analysis and literature review of the
prevalence, cause, risk factors, and outcome of VAP after
cardiac surgery, described in the current issue of the Jour-
nal. The study is of high-quality and sound statistical
design, and the data effectively summarize the benchmark
rates of VAP, responsible pathogens, risk factors for VAP,
and impact of VAP on patient outcomes.diovascular Surgery c Volume 148, Number 6 3155
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P
MAlthough the results of this exercise are not entirely novel
or new, the information presented should be readwith interest
by the cardiothoracic surgical community. The overall prev-
alence of VAP after cardiac surgery was 6.37%, but reached
35.2% in patients receiving mechanical ventilation for more
than 48 hours. Causative organisms were shown to be Pseu-
domonas aeruginosa or Staphylococcus aureus in the major-
ity of cases. Several risk factors were found to be associated
with VAP, including preoperative pulmonary disease or other
end-organ dysfunction, emergency surgery, intra-aortic
balloon pump use, cardiopulmonary bypass time, aortic
crossclamp time,mechanical ventilation time, reintervention,
and reintubation. Of note, many of these risk factors may be
modifiable in the perioperative period. The clinical conse-
quence of VAP was profound: the risk of mortality increased
15-fold and the mean intensive care unit (ICU) length of stay
increased 23-fold in patients diagnosed with VAP.
Although the synthesis of several studies into a meta-
analysis did not demonstrate any major new prevention or
treatment strategies for VAP, the analysis remains timely
and important because it reminds us of the scope and signif-
icance of VAP after cardiac surgery and should redirect
attention to institutional and national guidelines for VAP
prevention. At a time when the academic engines of the
cardiothoracic community are directed primarily toward
the design and optimization of new technologies and
emerging therapeutic avenues for the treatment of surgical
heart disease, VAP remains an old foe and a quiet killer of
patients that should not be forgotten. Prevention of VAP
should thus retain an important share of our attention.
Fortunately, several comprehensive guidelines exist to
inform the critical care community on best practices for
the prevention and treatment of VAP,3,4 including an
update from the American Thoracic Society published in
2005.5 The problem of VAP can be divided into prevention,
diagnosis, and treatment, with prevention being the critical
component because treatment of VAP is limited and out-
comes are generally poor. However, the key facets of VAP
prevention are relatively simple and should be familiar to
surgeons and ICU practitioners: These include basic infec-
tion control measures, such as hand washing and isolation
precautions to prevent the spread of resistant organisms;
use of sedation holidays, breathing trials, and standardized
protocols to expedite extubation and reduce the duration of
mechanical ventilation; semi-recumbent (30-45 upright)
patient positioning; deep venous thrombosis and stress ulcer
prophylaxis; oropharyngeal decontamination; and judicious
endotracheal tube and respiratory circuit care.
Given that guidelines for VAP prevention are well
established and predicated on basic infection control and
respiratory care practices, it is somewhat vexing that VAP
remains a pervasive clinical problem. Unfortunately, multi-
ple studies have shown that best-practice guidelines proven
to prevent VAP are inconsistently followed.6 A single-day3156 The Journal of Thoracic and Cardiovascular Surstudy of practice patterns in European cardiac ICUs found
poor compliance with basic VAP prevention guidelines
and reported that 33.5% of ventilated patients were not
maintained in a semi-recumbent position, among other defi-
ciencies.7 Another study similarly estimated that physician
adherence to VAP prevention measures varied between
20% and 100% in general ICUs.8 In keeping with this
theme, Jacobs and colleagues9 recently queried the Society
of Thoracic Surgeons database to examine variation in post-
operative ventilation time among patients undergoing iso-
lated coronary artery bypass grafting. Results showed that
ventilation times varied approximately 2-fold between
participating centers, and this variation could not be attrib-
uted to differences in patient characteristics.9 Given that
the duration of mechanical ventilation is perhaps the most
important contributor to VAP, variation in ventilation time
after heart surgery also may lead to variation in rates of
VAP. If so, standardization of extubation procedures after
heart surgery may represent a major quality improvement
opportunity for VAP prevention.9
CONCLUSIONS
Although unglamorous and occasionally overlooked, VAP
preventionmeasures are cheap and simple but require careful
attention to detail and a ‘‘back to basics’’ approach in the
cardiothoracic ICU. Given that cardiac surgeons continue to
oversee or provide the majority of critical care services for
our patients, it is important that we remain meticulous en-
forcers ofVAPprevention and champions of quality improve-
ment in our ICUs. The present study by He and colleagues1
reemphasizes the continued importance of this responsibility.
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